Company profile

Cytosorbents

cytosorbents.comHeadquarters: United States
51-200 employeesHybrid (Product + Service)
Cytosorbents logo

Primary focus

Hemoadsorption blood-purification technology for extracorporeal use.

Why it’s included

The company develops and manufactures hemoadsorption cartridges, including the named CytoSorb device, explicitly indicated for cytokine removal in septic shock and supported by company-sponsored clinical trials targeting sepsis and septic shock.

Relevant capabilities

  • Hemoadsorption therapy for extracorporeal blood purification
  • Design and manufacture of biocompatible porous polymer bead adsorbents
  • Integration of adsorption cartridges into extracorporeal circuits (dialysis/ECMO)
  • Performance testing and therapeutic‑area application evaluation
  • Development of hardware to enable independent therapy delivery
Commercial sectorExtracorporeal Hemoadsorption and Hemoperfusion Devices
Technology classesCytokine adsorption hemoperfusion devices

Relevant commercial products

  • CytoSorb
  • Disposable adsorption cartridge for extracorporeal blood and perfusate purification
  • PuriFi
  • Mobile standalone adsorption console

Relevant patents

5 families, 5 publications
  • Use of a hemocompatible porous polymer bead sorbent for removal of endotoxemia-inducing molecules US-11065600-B2
  • Method of treating inflammation US-10946040-B2
  • Methods for removal of toxins from blood using an extracorporeal circuit comprised of a hollow-fiber filter module and polymer sorbent in c... US-11202855-B2
  • Biocompatibility; for extracting cytokines and beta-2-microglobulin US-7875182-B2
  • Hemocompatibility modifiers for cross-linked polymeric material US-11020521-B2

← Back to what’s inside this report